April 25th 2024
A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.
Artificial Intelligence Tools Could Use ECGs to Predict Type 2, Prediabetes
August 10th 2022Called the DiaBeats algorithm, new research suggests leveraging the machine learning-based algorithm, combined with ECG recordings, could help predict increased risk of developing prediabetes and type 2 diabetes.
GnRH Agonists for Prostate Cancer Could Increase CVD Risk in Type 2 Diabetes
August 9th 2022New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.
Trial Suggests Time-Restricted Eating Could Aid in Weight Loss, Improve Blood Pressure
August 8th 2022Data from a 14-week randomized clinical trial suggests adherence to a time-restricted diet was associated with significant differences in weight loss and improvements in blood pressure compared to a typical diet.
Blood Protein Could Signal Increased Risk of Diabetes, Future Cancer Mortality
August 5th 2022An analysis of more than 20 years of follow-up data from more than 4000 patients in the Malmö Diet and Cancer Study shed light on associations between prostasin concentrations and risk of developing diabetes and cancer mortality.
CGM Can Improve Glucose Control, Reduce Spread of Infectious Disease in In-Hospital Settings
August 3rd 2022A retrospective study provides insight into the ability of CGM technology to improve glycemic control in in-hospital settings and, potentially, reduce the risk of spreading infectious diseases.
Endocrine Month in Review: July 2022
July 30th 2022Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.
Diabetes Dialogue: The Race to Cure T1D
July 29th 2022For the July 2022 episode of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to provide perspective on the latest advances in the fight to cure type 1 diabetes and offer insight into their experiences at the Practical Ways to Achieve Targets in Diabetes Care Conference held in Keystone, CO in mid-July.
In Type 1 Diabetes, Higher Insulin Doses Could Increase Cancer Risk
July 28th 2022An analysis of the DCCT and EDIC studies provides clinicians with insights into the risk factors associated with incident cancer diagnoses among patients with type 1 diabetes, suggesting those using higher daily doses of insulin had a more than 4-fold increase in risk of a cancer diagnosis.
Endocrine Case Report: Finger Swelling in T1D
July 23rd 2022Our latest case report from Brady Pregerson, MD, features a man in his 30s with a history of type 1 diabetes mellitus on insulin presenting to the emergency department for left index finger pain and swelling. Can you determine the correct diagnosis?
COVID-19 Infection Could Increase Risk of Developing Diabetes
July 19th 2022An analysis of data from more than 450,000 patients in the UK details an 81% increase in the net incidence of diabetes in the first 4 weeks after contracting COVID-19, which remained elevated through weeks 5-12, compared to those who did not contract COVID-19.
Medicare Advantage Beneficiaries Less Likely to Receive Newer Diabetes Medications
July 11th 2022An analysis comparing prescribing practices for Medicare Advantage beneficiaries against those in fee-for-service programs suggests Advantage patients were more likely to receive ACE inhibitors or ARBs, but 20% less likely to receive GLP-1 RAs and 9% less likely to receive SGLT2 inhibitors.
Diabetes Can Increase Mortality, Morbidity in Acromegaly
July 9th 2022An analysis from investigators in Sweden suggests patients with acromegaly with diabetes had a 58% greater risk of overall mortality and a more than 2-fold increase in risk of cardiovascular mortality compared to their counterparts without diabetes.